• Journal of Embryo Transfer
• /
• v.24 no.1
• /
• pp.1-14
• /
• 2009

Ovarian cancer is a significant cause of cancer-related death in women, but the main biological causes remain open questions. Hormonal factors have been considered to be an important determinant causing ovarian cancer. Recent studies have shown that gonadotropin-releasing hormone (GnRH)-I and its analogs have clinically therapeutic value in the treatment of ovarian cancer. In addition, numerous studies have shown that the potential of GnRH-II in normal reproductive system or reproductive disorder. GnRH-I receptors have been detected in approximately 80% of ovarian cancer biopsy specimens as well as normal ovarian epithelial cells and immortalized ovarian surface epithelium cells. GnRH-II receptors have also been found to be more widely expressed than GnRH-I receptors in mammals, suggesting that GnRH receptors may have additional functions in reproductive system including ovarian cancer. The signal transduction pathway following the binding of GnRH to GnRH receptor has been extensively studied. The activation of protein kinase A/C (PKA/PKC) pathway is involved in the GnRH-I induced anti-proliferative effect in ovarian cancer cells. In addition, GnRH-I induced mitogen-activated protein kinase (MAPK) activation plays a role in anti-proliferative effect and apoptosis in ovarian cancer cells and the activation of transcriptional factors related to cellular responses. However, the role of GnRH-I and II receptors, there are discrepancies between previous reports. In this review, the role of GnRH in ovarian cancer and the mechanisms to induce anti-proliferation were evaluated.

• Journal of Microbiology and Biotechnology
• /
• v.29 no.4
• /
• pp.658-664
• /
• 2019

Immunocontraception has been suggested as an optimal alternative to surgical contraception in animal species. Many immunocontraceptive vaccines have been designed to artificially produce antibodies against gonadotropin-releasing hormone-I (GnRH-I) which remove GnRH-I from the vaccinated animals. A deficiency of GnRH-I thereafter leads to a lack of gonadotropins, resulting in immunocontraception. In this study, we initially developed three immunocontraceptive vaccines composed of GnRH-I, GnRH-II, and a GnRH-I and -II (GnRH-I+II) complex, conjugated to the external domain of Salmonella Typhimurium flagellin. As the GnRH-I+II vaccine induced significantly (p < 0.01) higher levels of anti-GnRH-I antibodies than the other two vaccines, we further evaluated its immunocontraceptive effects in male rats. Mean testis weight in rats (n = 6) inoculated twice with the GnRH-I+II vaccine at 2-week intervals was significantly (p < 0.01) lower than in negative control rats at 10 weeks of age. Among the six vaccinated rats, two were non-responders whose testes were not significantly reduced when compared to those of negative control rats. Significantly smaller testis weight (p < 0.001), higher anti-GnRH-I antibody levels (p < 0.001), and lower testosterone levels (p < 0.001) were seen in the remaining four responders compared to the negative control rats at the end of the experiments. Furthermore, seminiferous tubule atrophy and spermatogenesis arrest were found in the testis tissues of responders. Therefore, the newly developed GnRH-I+II vaccine efficiently induced immunocontraception in male rats. This vaccine can potentially also be applied for birth control in other animal species.

• Clinical and Experimental Reproductive Medicine
• /
• v.33 no.2
• /
• pp.115-123
• /
• 2006

Objective: To investigate new signal transduction cascade through integrin, FAK and ERK in the suppressed cell proliferation by GnRH-I and -II. Method: Human endometrial cancer cells (HEC1A) were cultured under the following condition: DMEM/F12 (10% FBS). GnRH-I and -II were treated time (0, 5, 10, 15, 20, 30 min; 100 nM) and dose (10 nM or 100 nM; 20 min) dependent manner according to experimental purposes. Cell proliferation was measured using [$^3H$] thymidine incorporation assay. Immunoblotting was utilized to detect proteins. Results: GnRH-I and -II inhibited proliferation of HEC1A cells and induced expression of integrin ${\beta}3$. Phosphorylation of FAK and ERK were induced by GnRH-I and -II. Conclusion: GnRH inhibited cell proliferation via the expression of integrin and FAK, ERK phosphorylation.

• Molecules and Cells
• /
• v.25 no.1
• /
• pp.91-98
• /
• 2008

The Glu/$Asp^{7.32}$ residue in extracellular loop 3 of the mammalian type-I gonadotropin-releasing hormone receptor (GnRHR) interacts with $Arg^8$ of GnRH-I, conferring preferential ligand selectivity for GnRH-I over GnRH-II. Previously, we demonstrated that the residues (Ser and Pro) flanking Glu/$Asp^{7.32}$ also play a role in the differential agonist selectivity of mammalian and non-mammalian GnRHRs. In this study, we examined the differential antagonist selectivity of wild type and mutant GnRHRs in which the Ser and Pro residues were changed. Cetrorelix, a GnRH-I antagonist, and Trptorelix-2, a GnRH-II antagonist, exhibited high selectivity for mammalian type-I and non-mammalian GnRHRs, respectively. The inhibitory activities of the antagonists were dependent on agonist concentration and subtype. Rat GnRHR in which the Ser-Glu-Pro (SEP) motif was changed to Pro-Glu-Val (PEV) or Pro-Glu-Ser (PES) had increased sensitivity to Trptorelix-2 but decreased sensitivity to Cetrorelix. Mutant bullfrog GnRHR-1 with the SEP motif had the reverse antagonist selectivity, with reduced sensitivity to Trptorelix-2 but increased sensitivity to Cetrorelix. These findings indicate that the residues flanking $Glu^{7.32}$ are important for antagonist as well as agonist selectivity.

• The Korean Journal of Zoology
• /
• v.34 no.4
• /
• pp.491-499
• /
• 1991

The present experiment was carried out 1) to study the developmental topography of GnRH neuronal system and 2) to characterize the cellular localization of GnRH neurons in the prenatal brain development of the rat. At embryonic day (I) 14.5, immunoreactive cell bodies of GnRH were first seen in the nasal septum and in the ganglion terminate located in the ventral protion of the caudal olfactory bulb. Two days later (E 16.5), GnRH-containing neurons were observed at the level of olfactory tubercle and diagonal band of Broca, which is the first appearance in the intracerebral region. From 118.5, the topographic pattern of immunoreactive GnRH perikarya was similar to that of adult rats. The present data suggest that GnRH neurons were originated from the nasal septum and gradually extended to the hvpothalamic regions with increasing fetal age.

• Development and Reproduction
• /
• v.5 no.1
• /
• pp.81-88
• /
• 2001

Gonadotropin-releasing hormone (GnRH) has been known to play a role in the regulation of hCG secretion by human placenta. Recently, a gene encoding the second f개m of GnRH (GnRH-II) was identified in human. Herein, we demonstrate that GnRH-II is expressed in human placenta and assess GnRH-II expression by nested RT-PCR and immunohistochemistry in human placenta during the first trimester. We found that two altematively spliced transcripts of GnW-II mRNA were expressed in human placental tissues of first trimester and the shorter variant had a 21-bp deletion in GnRH-associated peptide (GAP). Immunoreactive GnRH-II was localized in both cytotrophoblastic and syncytiotrophoblastic cytoplasm. The immunostaining intensity was stronger in cytotrophoblast. Villous stromal cells also showed GnRH-II immunoreactiyiry. The results of our study report that the second isoform of GnRH (GnRH-II) is expressed in the first trimester human placenta and we suggest that GnRH-II may also play a regulatory role in maintenance of early pregnancy and hCG secretion in human placenta.

• Asian-Australasian Journal of Animal Sciences
• /
• v.11 no.1
• /
• pp.78-83
• /
• 1998

The objective of this study was to investigate the responsiveness of hypophysis and gonads to synthetic GnRH among prepubertal buffalo heifers at 12 months of age. Peripheral plasma FSH, LH, estradiol and progesterone level were measured in blood samples collected at 1 hr before and up to 18 days subsequent to the administration of $200{\mu}g$ GnRH (n=6) or saline (n=6) in Murrah buffalo heifers. The pretreatment peripheral plasma FSH, LH, estradiol and progesterone among GnRH treated heifers were $7.35{\pm}0.45ng/ml$, $1.08{\pm}0.3ng/ml$, $22.93{\pm}1.06pg/ml$ and $0.27{\pm}0.04ng/ml$ respectively. A quick elevation (p < 0.01) of FSH and LH within five min of GnRH administration was observed in all geifers. Although the peak FSH $(89.57{\pm}23.43ng/ml)$ and LH $(7.52{\pm}3.08ng/ml)$ reached by 10 min of GnRH administration, yet the animals differed both in terms of their amplitude response of FSH and LH release as well as in terms of time which animals took to exhiit maximum response to GnRH administration. The GnRH administration did not cause alteration in plasma estradiol and progesterone level. The present study suggests that the pituitary of 12 month buffalo heifers has capacity to synthesize and store of gonadotropin and have developed receptors for GnRH for a spike of gonadotropin release.

• Asian-Australasian Journal of Animal Sciences
• /
• v.11 no.4
• /
• pp.416-421
• /
• 1998

The objective of this study was to investigate the responsiveness of hypophysis and gonads to synthetic GnRH among noncycling Murrah buffalo heifers at 24 months of age. The plasma FSH, LH, estradiol and progesterone levels were measured in blood samples collected at 1 hour before and upto 18th day subsequent to the administration of GnRH ($(200 {\mu}g)$) or saline (2 ml). The pretreatment levels of plasma FSH, LH estradiol and progesterone among GnRH treated heifers (N = 6) were $11.55{\pm}0.57ng/ml$, $0.68{\pm}0.06ng/ml$, $19.84{\pm}0.82pg/ml$ and $0.45{\pm}0.07ng/ml$ respectively. A quick elevation of FSH (p < 0.01) and LH (p < 0.05) within 5 min of GnRH administration was observed in all the heifers. The peak FSH ($74.97{\pm}18.63ng/ml$) and LH ($3.09{\pm}0.54ng/ml$) level was obtained at 30 min of GnRH administration. The elevated level of plasma estradiol on 5th to 18th day, FSH on 7th to 9th day (n = 3) and the progesterone on 13th to 18th day (n = 2) of GnRH injection was obtained. The study indicates that gonads of buffalo heifers at 24 months of age are responsive of GnRH induced gonadotropin release for folliculogenesis and luteal tissue formation

• The Korean Journal of Zoology
• /
• v.37 no.4
• /
• pp.504-513
• /
• 1994

The present study was carried out 1) to show the ontogenic development of CA-and GnRH-containing nerve fobres in the median eminence, 2) to simultaneously demonstrate the synaptic contact between these two nenre fibres in the rat median eminence at the ultrastructural level using light and electron microscopic doublelabel immunostainlngs. GnRH-and CA-nenre terminals were detectable in the median eminence at embryonic day 19.5. The CA-newe terminals were obsenred in the entire legion of the extern31 lavers, while GnRH-newe terminals only in the lateral portion. At the 14th postnatal daw, both %ropes of nerve terminals showed a very similar distribution to those of adult one. In the median eminence of adult rats, a substantial overlap existed in the distribution of GnRH fibres with CA-containing nerve fibres. This overlap was most intense throughout the external palisade zone. Furthermore, an electron microscopic double label immunostaining showed that there was a close apposition of CA- and GnRH-nenre fobres. These axo-axonic contacts occurred frequently in the internal and palisade zones, i.e. at the level of the fobre preterminals. These morphological results suggest that the CA-mediated GnRH secretion may occur via sxo-axonic interaction in the median eminence.

• Journal of Veterinary Clinics
• /
• v.21 no.4
• /
• pp.384-394
• /
• 2004

This study was carried out to monitor the response of ovaries and cyst according to treatment with GnRH or combination of GnRH and $PGF_2{\alpha}$ in dairy cows with ovarian follicular cysts. Thirty cows were diagnosed as having follicular cysts by rectal palpation, ultrasonography and progesterone (P4) assays. Ten cows were treated with GnRH (control), and the other twenty were treated with $PGF_2{\alpha}$ at 10 days after GnRH treatment. All the animals were re-examined by ultrasonography and blood was collected for the measurement of plasma P4 concentration at day 0 (the day of treatment), day 7, day 10, day 13, day 24 and day 34, respectively. In 30 cows that were diagnosed with follicular cysts, mean plasma P 4 concentrations on day -II and day -I were 0.3 ng/ml and 0.4 ng/ml. On day 10 increased as 2.7$\pm$0.2 ng/ml. Mean cystic wall thickness by ultrasonography on day -11 and day -I were 2.1 mm and 2.2 mm. In 9 cows responded on luteinization of cystic wall, cystic wall thickness was 3.9$\pm$0.5 mm at day 10 after GnRH treatment. The responses of ovaries until day 10 after GnRH treatment included development of corpus luteum in the ovary bearing the cyst or in the contralateral ovary (12 cows), luteinization of cystic wall (6 cows) and clouding of the anechoic antrum of cysts (2 cows). The ovarian responses according to the combination of GnRH and $PGF_2{\alpha}$ included regression of the corpus luteum (12 cows), increase (1 cow) and no change (1 cow) of cyst size until last examination, and complete disappearance on day 13 (6 cows), 23 (6 cows) and 34 (4 cows). Combination treatment group of GnRH and $PGF_2{\alpha}$ showed a higher pregnancy rate within 100 days after initial treatment (40.0 vs 65.0%) and shorter intervals from the treatment to conception (45.4$\pm$25.8 vs 53.5$\pm$31.4 days) compared with control. It was concluded that the administration of $PGF_2{\alpha}$ following GnRH treatment is effective in shortening the interval from treatment to conception in cows with follicular cyst. Also, this study suggested that the response of the cyst according to treatment revealed various types. Therefore, veterinarians should pay attention to monitor of the response of cystic ovaries after treatment, specially no change, slowly decrease or increasement of cyst size after treatment.